Skyhawk Therapeutics veröffentlicht die Ergebnisse der cUHDRS-Unterkomponenten nach zwölf Monaten aus seiner klinischen Phase-1/2-Studie mit SKY-0515 bei der Huntington-Krankheit

Phase 2positiveSKY-0515Positive

AI Analysis

Summary

Skyhawk Therapeutics announced 12-month results from its Phase 1/2 study of SKY-0515 in Huntington's disease, showing positive and consistent trends across all four cUHDRS sub-components. The results support continued development of the candidate treatment for this neurodegenerative disease.

Clinical Trial Data

Phase

1/2

Primary Endpoint

Met

Outcome Details

12-month results showed positive and consistent trends across all four cUHDRS sub-components including Total Functional Capacity (TFC), Total Motor Score (TMS), and cognitive measures in patients receiving SKY-0515

Importance:6/10

Sentiment:

0.75

clinical_trialPhase_2Huntington_diseasepositive_dataneurodegeneration

Related Companies

$MEHA

Read the original article

Published by PR Newswire Biotech on July 1, 2026 12:50 PM

Read Original